AI Article Synopsis
- The study examines the laboratory monitoring frequency for adverse events related to outpatient parenteral antimicrobial therapy (OPAT) during treatments with cefazolin and ceftriaxone.
- It found an occurrence rate of 2.7 OPAT-related adverse events per 1000 sets of weekly lab tests.
- This suggests that less frequent lab monitoring could be both safe and acceptable for patients receiving these therapies.
Article Abstract
The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during cefazolin and ceftriaxone therapy is not well defined. We identified 2.7 OPAT-AEs per 1000 sets of weekly laboratory tests in this population, suggesting that less intensive laboratory monitoring may be safe and reasonable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10727193 | PMC |
| http://dx.doi.org/10.1093/ofid/ofad606 | DOI Listing |
Publication Analysis
Top Keywords
laboratory monitoring
12
adverse events
8
outpatient parenteral
8
parenteral antimicrobial
8
cefazolin ceftriaxone
8
serious adverse
4
laboratory
4
events laboratory
4
monitoring regimens
4
regimens outpatient
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!